We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

TD Cowen has lowered Eli Lilly’s price target from $1,050 to $960, but maintained a Buy rating, citing solid long-term ...

During the most recent episode of Mad Money, Jim Cramer opened the show by emphasizing just how much American companies ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

The 71st Fortune 500 ranks America’s largest companies by 2024 fiscal year revenue. Key healthcare takeaways from the most recent listing from Fortune, released June 2: 1. The list includes 12 ...

Investors flocked to shares of NRG as the energy supplier boosted capacity. UnitedHealth stock slumped, and the company’s CEO ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

The US drugmaker has stolen a march on Novo Nordisk by bringing a viable oral weight-loss medicine, orforglipron, into successful phase 3 clinical trials. An oral version is the holy grail for drugs ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...